Opendata, web and dolomites

PML-THERAPY SIGNED

HARNESSING PML NUCLEAR BODIES FOR LEUKAEMIA THERAPY

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PML-THERAPY project word cloud

Explore the words cloud of the PML-THERAPY project. It provides you a very rough idea of what is the project "PML-THERAPY" about.

therapeutically    screen    mechanistic    inactivated    translational    oxidative    dissect    knock    cancer    loose    needs    expression    bodies    exploring    drugs    acute    broad    modifications    integrate    restoration    patients    strategies    underlying    trioxide    nbs    modulating    mechanism    mutant    controls    regulated    mechanistically    cancers    sumoylated    selective    therapy    responsive    absolutely    nb    conjugation    blunts    generate    infections    basal    proteins    activates    redox    modulation    hif1a    biogenesis    ifn    lost    combination    normal    checkpoint    homeostasis    malignancies    mice    allele    ptm    resistance    medical    repertoire    degradation    npmc    leukaemias    bases    apl    libraries    manner    found    tax    ra    myeloid    expressing    viral    innovative    behaves    organizes    client    sensitive    somehow    oncogenesis    physiologically    signalling    explore    disruption    sumos    pressure    restore    rara    post    vivo    rb    critically    senescence    unmet    dependent    elaborate    exploration    downstream    pml    contributes    series    domains    first    chemical    nuclear    models    arsenic    multiple    incompletely    p53    acid    interferon    retinoic    stress    jak2    therapeutic    promyelocytic    cure    leukaemia    sensor    recruit    bind   

Project "PML-THERAPY" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙500˙000 €
 EC max contribution 2˙500˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 2˙400˙000.00
2    American University of Beirut LB (BEIRUT) participant 100˙000.00

Map

 Project objective

In acute promyelocytic leukaemia (APL), retinoic acid (RA) and Arsenic trioxide (As) bind PML/RARA and promote its degradation. Exploring the mechanistic bases for APL response to the RA/As combination, we found that upon PML/RARA degradation the normal PML allele activates a PML/P53 checkpoint absolutely required for APL cure in mice or patients. Physiologically, PML behaves as an oxidative stress sensor and contributes to redox homeostasis. PML organizes nuclear bodies (NBs), domains that recruit multiple client proteins and may facilitate their post-translational modifications (PTM), particularly conjugation of SUMOs. This somehow controls multiple downstream pathways such as P53, but also RB, HIF1A or interferon (IFN). In APL, NB-disruption blunts P53-driven senescence, contributing to oncogenesis and therapy resistance. Critically, PML expression and/or NB-formation are lost upon many viral infections or during cancer development. The mechanism(s) underlying the selective pressure to loose PML expression in multiple cancers remains incompletely understood. Our aim is to mechanistically dissect PML signalling in vivo and therapeutically restore it in malignancies where it is inactivated. We first propose a broad exploration of PML in mice to identify basal and stress-induced PML PTM and identify the repertoire of proteins sumoylated in a PML- dependent manner. We will generate a series of PML knock-in mutant mice and analyse their P53- regulated redox homeostasis. We will mechanistically explore PML/P53-driven senescence in three leukaemia models where we have evidence for basal or therapy-responsive NB-modulation: acute myeloid leukaemia expressing NPMc and IFN-sensitive Tax- or JAK2-driven leukaemias. We will screen chemical libraries for drugs modulating PML expression and/or NB biogenesis. Finally, we will integrate our findings to elaborate innovative therapeutic strategies based on restoration of the PML/P53 checkpoint in leukaemia with unmet medical needs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PML-THERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PML-THERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NeuroMag (2019)

The Neurological Basis of the Magnetic Sense

Read More  

sociOlfa (2020)

Learning from social scents: from territory to identity

Read More  

TechChild (2019)

Just because we can, should we? An anthropological perspective on the initiation of technology dependence to sustain a child’s life

Read More